FDG PET/CT for therapeutic response monitoring in multi-site non-respiratory tuberculosis.

BACKGROUND

Tuberculosis (TB) can produce positive signals during ¹⁸F-fluorodeoxyglucose positron emission/computed tomography (FDG PET/CT) scanning. Until now, there has been no better method than clinical assessment to evaluate the therapeutic response of non-respiratory TB (NRTB).

PURPOSE

To retrospectively assess the ability of FDG PET/CT to evaluate the response to anti-TB treatment in patients with NRTB.

MATERIAL AND METHODS

Three patients with multi-site NRTB underwent repeat PET/CT scans during anti-TB treatment. Changes in maximal standard uptake value (SUVmax) of the TB lesions on PET/CT images were analyzed between two scans. Initial PET/CT scans were performed before the start of anti-TB treatment, and later scans were performed after completion of the treatment.

RESULTS

Patient 1, a 63-year-old female, and patient 2, a 50-year-old male, were diagnosed as multi-site NRTB by biopsy. Patient 3, a 37-year-old male was diagnosed clinically. These patients demonstrated multiple FDG-avid lesions in whole body on initial PET/CT images. The highest SUVmax of patient 1, 2, and 3 were 13.6, 17.7, and 13.9 separately. After completion of the treatment, all positive signals of patient 1, 2, and 3 decreased to undetectable value on repeated PET/CT scans with intervals of 318 days, 258 days, and 182 days separately.

CONCLUSION

FDG PET/CT scan may be useful for monitoring responses to anti-TB treatment in patients with NRTB.